Ambry Genetics®, part of Konica Minolta Precision Medicine, developed the CARE (Comprehensive, Assessment, Risk, and Education) Program™. The CARE Program provides clinically actionable results to healthcare professionals to inform cancer screening and prevention, and effectively communicates this information to patients and their care teams.
Provides personalized cancer risk information
Facilitates recommendations for additional screening
Identifies at-risk family members
Integrates seamlessly into your workflow
Helps reduce missed patients across clinics and providers
Genetic testing should be offered to more individuals with suspected inherited cancer risk, but it also needs to be managed in an effective and efficient way. The CARE for Oncology Program streamlines this entire process so the focus can be on helping patients and providing accurate results, not time-consuming paperwork and communications logistics. Manage patient information between healthcare providers, clinics and genetic counselors in an all-in-one efficient platform.
The CARE for Oncology Program provides a complete platform for managing patients and their results:
Streamlined screening assessment to identify those at risk
Pre-test education and genetic testing services
Results received directly through the platform
Post-test counseling to those who qualify
There are numerous professional society guidelines indicating that genetic testing for hereditary cancer is an important part of medical care. The National Comprehensive Cancer Network® (NCCN®) states that “Genetic testing should be considered in appropriate high-risk individuals where it will impact the medical management of the tested individuals and/or their at-risk family members.”
The American Society of Clinical Oncology (ASCO) recommends that “genetic testing be offered to individuals with suspected inherited (genetic) cancer risk in situations where test results can be interpreted, and when they affect medical management of the patient.”1
Through the CARE for Oncology Program, eligible patients will receive genetic testing through Ambry Genetics. Due to Ambry’s extensive contracts with commercial payers (covering 95% of insured lives), testing is affordable and accessible for the majority of patients. Four out of five patients pay $0 and for those who do pay, they pay on average less than $100. For additional questions on billing, please contact Ambry at 949.900.5500 or billing@ambrygen.com.
A patient’s personal and family history of cancer will be evaluated to determine if they are eligible for hereditary cancer genetic testing. Our program uses National Comprehensive Cancer Network (NCCN) genetic testing criteria, which outline various factors that may indicate a need for genetic testing, such as type of cancer, age of diagnosis, and number of family members with cancer. Any patient who meets these criteria will be offered genetic testing.
1. ascopubs.org/doi/10.1200/JCO.2015.63.0996
2. Z. Kakushadze, et al, in September 2017-Cornell University